Medical References for WegoKW
This page lists the main source categories and landmark studies used across WegoKW articles about Wegovy in Kuwait, semaglutide, obesity treatment, and related medications.
Core product and regulatory documents
- Kuwait and regional approved product leaflets for Wegovy when available locally.
- Official prescribing information and patient guides from Novo Nordisk and other regulators.
- Regulatory announcements and pricing updates relevant to Kuwait pharmacies.
Major Wegovy and semaglutide trials
- STEP 1: semaglutide 2.4 mg for adults with overweight or obesity.
- STEP 2: semaglutide in adults with obesity and type 2 diabetes.
- STEP 4: weight regain after withdrawal versus continued treatment.
- STEP 5: longer-term weight-management data.
- SELECT: cardiovascular outcomes with semaglutide 2.4 mg.
Comparison and obesity-treatment sources
- SURMOUNT studies for tirzepatide and Mounjaro.
- Trials comparing semaglutide with liraglutide or other weight-loss options.
- Bariatric surgery outcome summaries from major surgical societies and long-term obesity literature.
How to read source markers on the site
Some articles use shorthand source markers such as step1_nejm or select_trial inside the text. These labels point to the study, guideline, or regulatory document used for that claim. They are included to make article updates easier across both Arabic and English pages.